Iovance Biotherapeutics grants 140,860 inducement stock options

Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering an aggregate of 140,860 shares of its common stock to twenty-seven new, non-executive employees. The awards were granted on June 18, 2026, under the company's Amended and Restated 2021 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.91, which was the closing price on the grant date, and vests over a three-year period.